97 related articles for article (PubMed ID: 16454854)
1. Eligibility criteria for antiviral therapy in HCV-positive patients: similar things to (almost) similar people.
Giannini EG; Romagnoli P; Testa R
Am J Gastroenterol; 2006 Feb; 101(2):406-7. PubMed ID: 16454854
[No Abstract] [Full Text] [Related]
2. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders.
Chainuvati S; Khalid SK; Kancir S; Shea M; Edwards J; Sernyak M; Wongcharatrawee S; Garcia-Tsao G
J Viral Hepat; 2006 Apr; 13(4):235-41. PubMed ID: 16611189
[TBL] [Abstract][Full Text] [Related]
3. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
[TBL] [Abstract][Full Text] [Related]
4. Towards a better understanding of HCV transmission and course of infection.
Berger A; Doerr HW
Infection; 2004 Jun; 32(3):125. PubMed ID: 15188069
[No Abstract] [Full Text] [Related]
5. Identified cases of acute hepatitis C from computerized laboratory database: a hospital-based epidemiological and clinical study.
Hung CH; Lu SN; Wang JH; Hung SF; Chen CH; Hu TH; Lee CM; Changchien CS
J Infect; 2008 Apr; 56(4):274-80. PubMed ID: 18346790
[TBL] [Abstract][Full Text] [Related]
6. Assessment of specific antibodies to F protein in serum samples from Chinese hepatitis C patients treated with interferon plus ribavarin.
Gao DY; Zhang XX; Hou G; Jin GD; Deng Q; Kong XF; Zhang DH; Ling Y; Yu DM; Gong QM; Zhan Q; Yao BL; Lu ZM
J Clin Microbiol; 2008 Nov; 46(11):3746-51. PubMed ID: 18832124
[TBL] [Abstract][Full Text] [Related]
7. Treatment and vaccination for hepatitis C: present and future.
Jawaid A; Khuwaja AK
J Ayub Med Coll Abbottabad; 2008; 20(1):129-33. PubMed ID: 19024206
[TBL] [Abstract][Full Text] [Related]
8. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma.
La Mura V; De Renzo A; Perna F; D'Agostino D; Masarone M; Romano M; Bruno S; Torella R; Persico M
J Hepatol; 2008 Oct; 49(4):557-63. PubMed ID: 18678434
[TBL] [Abstract][Full Text] [Related]
9. [Hepatitis C virus-associated glomerulonephritis].
Yamabe H
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):550-3. PubMed ID: 15359860
[No Abstract] [Full Text] [Related]
10. [Clinical value of the detection of hepatitis C virus core antigen].
Lu YC; Jiang ZY; Kuang YL; Chen WS; Tan YZ; Li DR
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Jul; 23(7):635-7. PubMed ID: 17618587
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV.
Deterding K; Tegtmeyer B; Cornberg M; Hadem J; Potthoff A; Böker KH; Tillmann HL; Manns MP; Wedemeyer H
J Hepatol; 2006 Dec; 45(6):770-8. PubMed ID: 17034895
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus virology and new treatment targets.
Meier V; Ramadori G
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin.
Boo I; Fischer AE; Johnson D; Chin R; Giourouki M; Bharadwaj M; Bowden S; Torresi J; Drummer H
J Clin Virol; 2007 Aug; 39(4):288-94. PubMed ID: 17569577
[TBL] [Abstract][Full Text] [Related]
14. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
[TBL] [Abstract][Full Text] [Related]
15. Novel hepatitis C drugs in current trials.
Kronenberger B; Welsch C; Forestier N; Zeuzem S
Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
Cristina J; del Pilar Moreno M; Moratorio G
Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
[TBL] [Abstract][Full Text] [Related]
17. Prediction of the efficacy of antiviral therapy for hepatitis C virus infection by an ultrasensitive RT-PCR assay.
Kinai E; Hanabusa H; Kato S
J Med Virol; 2007 Aug; 79(8):1113-9. PubMed ID: 17596840
[TBL] [Abstract][Full Text] [Related]
18. [Epidemiologic and therapeutic status study of patients with hepatitis C].
Xu M; Shi HY; Cai WP
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Apr; 25(2):135-6. PubMed ID: 21863640
[TBL] [Abstract][Full Text] [Related]
19. The way forward in HCV treatment--finding the right path.
Manns MP; Foster GR; Rockstroh JK; Zeuzem S; Zoulim F; Houghton M
Nat Rev Drug Discov; 2007 Dec; 6(12):991-1000. PubMed ID: 18049473
[TBL] [Abstract][Full Text] [Related]
20. An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance.
Humar A; Washburn K; Freeman R; Paya CV; Mouas H; Alecock E; Razonable RR;
Liver Transpl; 2007 Oct; 13(10):1422-7. PubMed ID: 17902128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
